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Regions and Countries of the European Union (total 27 countries) 
(Note that the italicized countries—Iceland, Norway and Switzerland—are not EU member states; they 
are included only for comparison, and are not included in the EU average) 
 
Central-East and Eastern Europe (10 countries): Bulgaria, Czech Republic, Estonia, Hungary, Latvia, 
Lithuania, Poland, Romania, Slovakia, Slovenia 
Nordic Countries (5 countries): Denmark, Finland, Iceland, Norway, Sweden 
Central-West and Western Europe (9 countries): Austria, Belgium, France, Germany, Ireland, 
Luxembourg, Netherlands, Switzerland, UK 




















































































































































































































Austria  4.0%  5.3%  62.5%  11.2%  11.4%  5.5%  4.6%  7.5%  62.9%  14.9%  5.8%  4.3% 
Belgium  2.8%  6.2%  65.0%  10.9%  10.5%  4.6%  6.8%  5.6%  64.5%  14.3%  5.2%  3.5% 
Bulgaria  9.2%  4.7%  60.4%  10.4%  10.4%  4.9%  20.7%  4.9%  53.5%  12.7%  4.8%  3.3% 
Cyprus  5.7%  5.0%  68.6%  9.7%  8.2%  2.9%  8.8%  6.2%  67.5%  12.0%  3.6%  1.9% 
Czech Republic  2.9%  6.7%  56.7%  11.9%  13.8%  8.1%  4.2%  12.5%  55.9%  15.2%  6.6%  5.7% 
Denmark  0.5%  2.0%  69.7%  11.6%  11.2%  4.9%  0.5%  5.3%  70.8%  14.9%  5.2%  3.3% 
Estonia  6.5%  17.8%  46.0%  10.1%  12.2%  7.5%  10.9%  17.1%  47.1%  13.4%  6.0%  5.6% 
Finland  2.8%  4.7%  65.7%  11.1%  10.8%  4.8%  5.8%  2.8%  68.1%  14.7%  5.2%  3.4% 
France  1.5%  2.8%  67.9%  11.5%  11.2%  5.0%  1.8%  5.3%  69.1%  14.9%  5.3%  3.5% 
Germany  1.1%  2.0%  68.7%  11.7%  11.4%  5.1%  1.0%  1.9%  73.2%  15.3%  5.3%  3.3% 
Greece  5.5%  7.4%  63.6%  10.2%  9.4%  3.9%  11.5%  14.2%  51.9%  12.9%  5.2%  4.2% 
Hungary  3.8%  9.3%  57.3%  11.1%  12.0%  6.4%  6.2%  9.5%  61.0%  14.3%  5.4%  3.7% 
Iceland  4.5%  8.0%  72.6%  7.9%  5.5%  1.5%  8.0%  6.0%  74.0%  9.2%  2.1%  0.7% 
Ireland  15.0%  4.4%  53.8%  10.2%  10.9%  5.6%  15.9%  3.8%  55.7%  14.1%  5.8%  4.7% 
Italy  4.6%  3.1%  70.9%  10.0%  8.4%  3.0%  9.9%  4.4%  66.2%  13.0%  4.2%  2.4% 
Latvia  5.0%  8.7%  49.7%  11.7%  14.9%  9.9%  11.0%  17.0%  41.4%  14.0%  7.4%  9.2% 
Lithuania  3.7%  5.5%  60.4%  11.6%  12.4%  6.4%  13.5%  10.9%  52.0%  13.5%  5.6%  4.5% 
Luxembourg  5.1%  5.1%  63.2%  10.9%  10.8%  4.9%  8.7%  6.2%  61.4%  14.3%  5.4%  4.0% 





Netherlands  5.1%  9.9%  63.4%  9.6%  8.6%  3.4%  9.6%  14.7%  55.8%  12.3%  4.5%  3.0% 
Norway  2.0%  5.0%  75.7%  8.9%  6.5%  1.9%  2.3%  5.6%  78.5%  10.4%  2.4%  0.9% 
Poland  7.3%  8.3%  55.4%  10.8%  11.9%  6.4%  14.6%  10.2%  51.9%  13.4%  5.5%  4.4% 
Portugal  15.8%  12.9%  44.1%  9.5%  11.1%  6.6%  27.0%  17.4%  31.2%  10.8%  5.8%  7.8% 
Romania  7.0%  13.2%  48.1%  10.7%  12.9%  8.1%  13.2%  24.6%  35.9%  12.1%  6.3%  7.9% 
Slovakia  7.8%  13.9%  48.8%  10.3%  12.1%  7.1%  5.1%  12.3%  58.7%  14.3%  5.6%  4.1% 
Slovenia  3.9%  3.6%  60.1%  11.9%  13.2%  7.2%  5.8%  9.5%  58.5%  15.0%  6.2%  4.9% 
Spain  8.0%  18.8%  46.0%  9.6%  11.1%  6.5%  27.6%  23.6%  27.2%  9.5%  5.1%  7.0% 
Sweden  4.4%  5.3%  70.4%  9.5%  7.8%  2.7%  5.8%  8.8%  68.1%  11.9%  3.5%  1.8% 
Switzerland  6.1%  3.2%  65.6%  10.7%  10.1%  4.3%  11.5%  3.8%  60.7%  14.5%  5.6%  3.9% 
United Kingdom  7.5%  1.2%  64.8%  11.0%  10.7%  4.8%  8.5%  2.2%  65.9%  14.5%  5.3%  3.6% 
Total 
(European Union) 
5.0%  6.1%  62.1%  10.8%  10.9%  5.2%  9.5%  8.5%  59.1%  13.6%  5.2%  4.1% 
For comparison: 
Russian Federation 



































































Total per capita 
consumption (litres 
pure alcohol)* 
Recorded per capita 
consumption (average 
2008–2010) 
Unrecorded per capita 
consumption Pattern of Drinking 
Austria 13.00 12.30 0.7 1 
Belgium 12.00 11.00 1.0 1 
Bulgaria 11.45 10.25 1.2 2 
Cyprus 9.53 8.53 1.0 1 
Czech Republic 16.61 15.11 1.5 3 
Denmark 12.86 10.86 2.0 2 
Estonia 14.05 13.35 0.7 3 
Finland 12.27 9.97 2.3 3 
France 12.70 12.30 0.4 1 
Germany 12.87 11.87 1.0 1 
Greece 10.55 8.67 1.8 2 
Hungary 14.15 11.65 2.5 3 
Iceland 7.93 7.53 0.4 3 
Ireland 12.87 11.87 1.0 3 






review: around 4.0 
3 
Lithuania 13.02 12.62 0.4 3 
Luxembourg 12.76 11.76 1.0 1 
Malta 8.01 7.61 0.4 1 
Netherlands 9.73 9.23 0.5 1 
Norway 8.30 6.7 1.6 3 
Poland 13.60 10.60 3.0 3 
Portugal 13.43 11.43 2.0 1 
Romania 16.30 13.30 3.0 3 
Slovakia 14.59 11.59 3.0 3 
Slovenia 15.31 12.31 3.0 3 
Spain 13.07 11.67 1.4 1 
Sweden 8.85 8.15 1.7 3 
Switzerland 10.76 10.26 0.5 1 
United Kingdom 12.52 10.82 1.7 3 
EU 12.45 10.85 1.6 2.1 







* Note that for the “total per capita consumption,” the recorded average was for 2008–2010, plus the unrecorded estimate. In the 
red-shaded countries, adult consumption of alcohol is equal to or greater than 130% of the EU average. In the green-shaded 
25 
 
countries, consumption is equal to, or less than, 70% of the EU average. (Source: WHO Regional Office for Europe;29 Global 






















































































month never  
do not 
know 
Austria 17% 19% 16% 23% 24% 1% 
Belgium 12% 16% 15% 21% 36% 0% 
Bulgaria 8% 10% 9% 15% 57% 1% 
Cyprus 9% 17% 7% 12% 55% 0% 
Czech Rep. 7% 17% 20% 32% 24% 0% 
Denmark 7% 15% 24% 37% 17% 0% 
Estonia 4% 14% 23% 26% 32% 1% 
Finland 5% 17% 23% 33% 22% 0% 
France 7% 13% 15% 20% 45% 0% 
Germany 14% 22% 15% 23% 25% 1% 
Greece 15% 19% 12% 20% 34% 0% 
Hungary 11% 13% 16% 20% 40% 0% 
Ireland 12% 32% 18% 22% 14% 2% 
Italy 16% 14% 8% 12% 50% 0% 
Latvia 3% 8% 15% 23% 50% 0% 
Lithuania 6% 8% 14% 21% 51% 0% 
Luxembourg 6% 12% 24% 35% 23% 0% 
Malta 7% 19% 12% 31% 30% 1% 
Netherlands 9% 14% 15% 24% 38% 0% 
Poland 3% 16% 18% 34% 26% 3% 
Portugal 20% 8% 9% 12% 50% 1% 
Romania 19% 20% 13% 19% 27% 2% 
Slovakia 5% 12% 21% 31% 30% 1% 
Slovenia 8% 10% 18% 22% 42% 0% 
Spain 15% 19% 13% 20% 33% 0% 
Sweden 2% 11% 20% 32% 35% 0% 
UK 14% 20% 14% 20% 31% 1% 







































































































Colour Codes for EU Regions and Countries 
 
The European Union (total 27 countries): blue 
 
Central-East and Eastern Europe (10 countries): Bulgaria, Czech Republic, Estonia, Hungary, Latvia, 
Lithuania, Poland, Romania, Slovakia, Slovenia: red 
Nordic Countries (5 countries): Denmark, Finland, Iceland, Norway, Sweden: grey 
Central-West and Western Europe (9 countries): Austria, Belgium, France, Germany, Ireland, 
Luxembourg, Netherlands, Switzerland, UK: yellow 
Southern Europe (6 countries): Cyprus, Greece, Italy, Malta, Spain, Portugal: light grey 
(Note that the italicized countries—Iceland, Norway and Switzerland—are not EU member states; they 
























































































Cancer  17,358  8,668  15.9%  30.7% 
CVD (other than IHD)  7,914  3,127  7.2%  11.1% 
Mental and neurological disorders  10,868  2,330  9.9%  8.3% 
Liver cirrhosis  28,449  10,508  26.0%  37.2% 
Unintentional injury  24,912  1,795  22.8%  6.4% 
Intentional injury  16,562  1,167  15.1%  4.1% 
Other detrimental  3,455  637  3.2%  2.3% 
Total detrimental  109,517  28,232  100.0%  100.0% 
 
Beneficial effects 
IHD  14,736  1,800  97.8%  61.1% 
Other beneficial  330  1,147  2.2%  38.9% 







































































































































































Detrimental effects  Men Women Men  Women
Cancer  251,891 151,671 6.9%  17.5%
CVD (other than IHD)  128,336 25,969 3.5%  3.0%
Mental and neurological disorders  1,691,310 382,584 46.3%  44.2%
Liver cirrhosis  512,560 212,676 14.0%  24.6%
Unintentional Injury  634,959 50,936 17.4%  5.9%
Intentional injury  347,225 24,147 9.5%  2.8%
Other detrimental  83,640 18,149 2.3%  2.1%
Total detrimental  3,649,921 866,131 100.00%  100.00%
Beneficial effects   
IHD  275,588 87,887 94.8%  48.3%
Other beneficial  15,049 94,054 5.2%  51.7%



































































Health Burden  Numbers    Percentage of total 
Deaths  Men Women Men  Women
Low birth weight  62 45 1.1%  2.1%
Violence  1,586 685 28.5%  31.9%
Transport injuries  3,916 1,416 70.4%  66.0%
Total  5,564 2,147 100.0%  100.0%
DALYs   
Low birth weight  2,685 2,063 1.7%  3.5%
Violence  47,956 18,967 30.2%  31.7%
Transport injuries  108,170 38,719 68.1%  64.8%

























































Men  Women  Men  Women  Men  Women 
Deaths             
  15 to 34  8,037  972  11.1%  3.5%  61.1%  54.9% 
  35 to 64  67,155  16,430  11.1%  5.4%  82.6%  69.9% 
  Total  75,191  17,403  11.1%  5.3%  79.6%  68.8% 
PYLL             
  15 to 34  227,083  26,573  10.8%  3.3%  59.4%  54.5% 
  35 to 64  1,034,575  242,578  12.3%  5.7%  79.5%  67.5% 
  Total  1,261,658  269,151  12.0%  5.3%  74.9%  66.0% 
DALYs             
  15 to 34  1,231,634  249,557  17.2%  4.2%  86.9%  93.7% 
  35 to 64  1,705,044  412,395  11.4%  3.5%  87.8%  98.7% 
























































































affected Year Source 
Austria 2.5 7.5 66,800 204,800 2008 See reference 86 
Belgium 1.9 5.4 51,800 177,100 2001 
median of two major surveys: WMHS (corrected), and Belgian Health Survey 
2001, cf. GSRA 
Bulgaria 1.4 7.3 35,900 184,500 2004 See reference 87 
Cyprus 1.6 5.3 4,400 13,800 2004 See reference 87 
Czech 
Republic 0.8 5.0 27,600 173,400 2004 WHS 
Denmark 1.9 4.8 32,300 83,000 2005 See reference 88 
Estonia 2.1 11.0 9,500 45,400 2004 See reference 87 (own calculations) 
Finland 1.9 7.2 31,400 121,500 2000 See reference 89 for under 30-year-olds; 90 for 30-64 year-olds (see also 91) 
France 1.5 5.3 284,700 1,001,700 2001-2002 WMHS, adjusted 
Germany1 1.3 5.4 338,900 1,445,000 1997-1999 See reference 82-83 (personal communication) 
Greece 1.5 4.8 53,400 173,800 2004 See reference 87 
Hungary2 3.4 18.3 114,800 598,600 2004 See reference 87 
Iceland 1 3.3 910 3,100 2004 See reference 87 
Ireland 2.0 6.4 26,600 86,100 2004 See reference 87 
Italy 0.5 0.8 93,600 149,800 2001-2003 See reference 92 (adjusted) 
Latvia3 1.6 8.4 12,400 60,300 2004 See reference 87 (own calculations) 
Lithuania 1.9 9.9 21,600 104,200 2004 See reference 87 (own calculations) 
Luxembourg 1.4 5.4 2,000 8,000 2000 median of France and Germany 
Malta 0.8 2.8 1,000 3,800 2004 See reference 87 
Netherlands4 0.5 1.0 26,000 53,100 2007/2009 See reference 93 
Norway 3.5 10.5 50,000 154,500 1994-1997 See reference 94 
Poland5 1.6 8.4 205,500 1,058,200 2004 See reference 87 
Portugal 1.7 5.6 58,600 187,700 2004 See reference 87 (we asked for new data from the 2008 survey) 
59 
 
Romania 0.7 2.2 50,000 155,000 2007 See reference 95 et al., 2009 (adjusted)  
Slovakia 1.1 10.2 20,200 184,800 2000/2001 MCSS 
Slovenia 2.0 10.5 13,200 71,300 1999 GSRA (adjusted for screening scale) 
Spain 0.2 1.2 28,410 173,600 2000/2001 WMHS, adjusted 
Sweden 3.3 7.7 91,200 219,400 1998-2003 PART study, cf. 69 
Switzerland 1.6 8.1 39,300 194,300 2007 See reference 96 
UK6 
(England only) 
3.6 9.3 683,300 1,745,500 2007 
http://www.ic.nhs.uk/webfiles/publications/alcoholeng2009/Final%20Format%20dr
aft%202009%20v7.pdf 
EU 1.5 5.4 2,400,00 8,500,000  own calculations 
For comparisons     
Russia 3.9 18.0 2,104,800 8,888,700 2004 
Based on treatment data from Kirzhanova, V.V., National Research Centre of 
Narcology, under the Ministry of Health and Social Development of Russia, 
Moscow7 
 
Note: The red-shaded cells indicate more than 150% of the EU average, and the green-shaded cells less than 50%. If the male and female figures have the same 
shading, the country name is also shaded. 
Abbreviations for Data Sources 
GSRA: Global Status Report on Alcohol97 
MCSS: Multi-Country Survey Study98 
WHS: World Health Survey99 
WMHS: World Mental Health Survey100 
Notes on Table 8 
1 There are several regional studies in Germany (see overview in reference 69), but this is the latest national survey with comparable methodology. The next 
national mental health survey is ongoing. 
2 Indirect estimations are around 8% for both genders combined, based on a variant of Jellinek's formula (see 
http://www.gencat.cat/salut/phepa/units/phepa/pdf/phepa_final_report_annex4_hungary.pdf) 
3 A recent general-population survey from Latvia in 2011 found prevalence rates of 21% for men, and 4% for women, using standardized methodology (CIDI; 
personal communication from M. Trapencieris, from the Latvian Centre for Disease Control and Prevention).  
4 The prevalence of abuse was found to be 5 times higher in the Netherlands. AUDs have been stable for the past decade, but AD estimates had been markedly 
higher in past surveys. 
5 The prevalence of AD in primary health care in Poland was found to be 19%, using the CAGE screening scale.101 
6 Other UK estimates include the one cited by the National Institute for Health and Clinical Excellence,103 which amounted to 6% of men and 2% of women. 
7 The Russian treatment multiplier used was quite conservative. We estimated that 33% of urban dwellers with AD are treated, and 10% of rural dwellers. For 



























  Deaths (per 100,000 people)   PYLL (per 100,000 people)   DALYs (per 100,000 people) 
Country Women Men Total   Women Men Total   Women Men Total 
Austria 0.73 4.26 2.52  12.2 66.1 39.5  118.6 612.0 368.2 
Belgium 0.62 2.63 1.63  11.4 47.1 29.4  112.5 337.4 225.7 
Bulgaria 0.06 1.65 0.85  1.2 26.0 13.5  94.7 527.3 309.7 
Cyprus 0.01 0.04 0.02   0.1 0.6 0.3   0.1 368.3 179.2 
Czech Republic 0.50 2.01 1.26  8.9 32.0 20.5  74.5 623.4 349.9 
Denmark 2.11 10.18 6.19   34.3 154.6 95.0   148.8 738.0 446.2 
Estonia 3.25 16.47 9.59   55.0 285.6 165.7   230.2 1622.2 898.2 
Finland 0.95 5.70 3.35  15.0 101.9 59.0  156.7 1009.1 587.6 
France 1.19 6.68 3.93  20.6 114.8 67.7  146.5 751.0 448.5 
Germany 1.30 6.56 3.96  21.4 109.2 65.9  132.4 774.4 457.8 
Greece 0.01 0.26 0.14   0.3 5.1 2.7   100.1 514.8 309.4 
Hungary 0.75 5.92 3.30   12.8 94.6 53.1   251.7 1919.7 1073.8 
Iceland 0.25 0.85 0.56  4.8 16.1 10.6  82.8 407.9 248.3 
Ireland 0.92 1.91 1.42  15.2 39.0 27.2  138.5 662.0 402.1 
Italy 0.06 0.29 0.17   1.2 4.8 3.0   51.5 77.2 64.4 
Latvia 0.45 3.38 1.86   8.0 56.7 31.5   189.4 1444.5 794.9 
Lithuania 0.19 1.44 0.79   3.8 25.1 14.1   215.1 1640.7 903.3 
Luxembourg 1.09 5.16 3.15  20.9 84.7 53.2  140.7 694.7 420.8 
Malta 0.00 0.30 0.15   0.0 6.1 3.1   66.6 345.0 207.9 
Netherlands 0.21 1.20 0.71  3.2 19.7 11.5  96.1 758.9 430.9 
Norway 0.47 4.08 2.30   8.8 58.2 33.9   301.2 1314.5 815.5 
Poland 0.62 7.34 3.95  10.9 128.5 69.2  115.4 685.8 398.3 
Portugal 0.15 1.40 0.77  2.8 24.3 13.4  113.7 591.2 349.4 
Romania 0.80 4.69 2.74  13.1 77.5 45.1  142.4 772.0 455.5 
Slovakia 0.00 0.04 0.02   0.0 0.6 0.3   90.5 1164.4 624.5 
Slovenia 1.28 6.52 3.94  21.0 107.9 65.0  114.0 579.4 349.8 
Spain 0.10 0.87 0.49   1.7 13.5 7.7   21.2 160.3 91.4 
Sweden 0.81 4.19 2.53   11.5 62.6 37.5   282.7 969.7 631.6 
Switzerland 0.87 2.61 1.74   14.7 40.0 27.4   116.4 562.0 339.7 
United Kingdom 0.65 1.91 1.28  12.1 34.2 23.1  189.4 939.3 562.9 
Total (European 
Union) 0.68 3.83 2.26   11.7 64.5 38.1   121.1 654.9 388.5 
For comparison:            






Note: The red-shaded countries had an AD-related burden of disease (DALYs) that was more than 50% above the 












































































































































































































Health burden  Injuries; blackouts; 
hours of drunkenness; 
alcohol-dependent 




Injury (e.g. from child neglect or 
drunk driving); stress-related 
problems for other family 
members; FASD; interpersonal 
violence 




for health problems 
caused by alcohol; 
FASD 
Social burden131  Decreases in 
functionality associated 
with AD (blackouts, 
hours of drunkenness); 
decline in social role; 
loss of friendships; 
stigma 
Problems with parental roles, 
partnership roles, and caregiver 
roles (e.g. to children, parents) 
Teamwork problems; 
others having to 
compensate for lack of 
productivity 
Social costs of alcohol; 
vandalism 
Economic burden  Depends on country 
and socio-economic 
status; often cost of 
alcohol plus cost of 
possible job loss, or 
absenteeism 
Financial problems resulting 
from the health and social 
consequences of alcohol; 
negative effects on family 
budgets and household 
expenses 
Absenteeism and other 
productivity costs (mainly 
suboptimal performance 
when on the job, and 
short-term disability) 
Productivity losses; 
health care costs 
(including treatment of 
AD); costs in the legal 









 Burdens  Individual131  Family132  Work130  Society128 
Health burden  Morbidity from diseases 
caused or worsened by 
AD and associated 
premature mortality 
Injury (e.g. from child 
neglect or drunk driving); 
stress-related problems 
for other family members; 
FASD; interpersonal 
violence 
Injury Acute care 
hospitalizations for health 




Social burden131  Decreases in functionality 
associated with AD 
(blackouts, hours of 
drunkenness); decrease 
in social role; loss of 
friendships; stigma 
Problems with parental 
roles, partnership roles, 
and roles as caregiver in 
general (e.g. to parents) 
Team problems; others 
having to compensate for 
lack of productivity 
Social costs of alcohol; 
vandalism 
Economic burden  Dependent on society 
and on socio-economic 
status of person with AD; 
often cost of alcohol plus 
cost of possible job loss 
or absenteeism; possible 
social drift downwards 
Financial problems 
resulting from health and 
social consequences of 
alcohol impacting on 
family budget and 
household expenses 
Absenteeism and other 
productivity costs (mainly 
suboptimal performance 
when working and 
disability, short- and long-
term); replacement costs 
in case of premature 
mortality or long-term 
disability 
Productivity losses; 
health care costs; costs in 














































































































































Main psychotherapy used 
(abbreviations below) 
Main pharmacotherapy used in 
rehabilitation phase 
Austria No Yes Yes Yes wide variety used Acamprosate, Naltrexone, Disulfiram 
Belgium No No Yes Yes counselling; family-oriented interventions Acamprosate, Disulfiram 
Bulgaria No No Yes Yes multidisciplinary (12-step oriented), CBT Naltrexone, Disulfiram (not officially registered) 
Cyprus Yes No Yes No CBT, MET, relapse prevention,  family-oriented 
Mainly benzodiazepines for withdrawal; 
Acamprosate for rehabilitation treatment 
Czech Republic No Yes Yes Yes BI, CBT, MET, family  therapy / intervention? Acamprosate, Naltrexone, Disulfiram 
Denmark No Yes No Yes MET, CBT Acamprosate, Naltrexone, Disulfiram 
Estonia No* No Yes Yes CBT, group therapy, family therapy Disulfiram 
Finland No Yes No Yes CBT, MET, Minnesota model, AA 
Naltrexone, Disulfiram, Nalmefene 
(Acamprosate only under special 
licence) 
France Yes No Yes Yes CBT, group therapy, self-help Acamprosate, Naltrexone, Disulfiram 
Germany Yes Yes Yes Yes CBT, family, ergo & socio therapy Acamprosate, Disulfiram 
Greece No No Yes Yes CBT Naltrexone, Disulfiram (rarely) 
Hungary Yes No Yes Yes CBT, MET, family, problem &  group therapy Acamprosate, Naltrexone, Disulfiram 
Ireland No No Yes Yes Minnesota model, MI, CBT (AA aftercare) Acamprosate, Disulfiram 
Italy No No Yes Yes family, group & individual counselling Disulfiram, chlordiazeposside 
Latvia No Yes Yes Yes wide variety used Disulfiram (Acamprosate and Naltrexone only rarely) 
Lithuania No No Yes Yes Minnesota model, group therapy Naltrexone, Disulfiram 
78 
 
Luxembourg No No Yes Yes MI, CBT, family & group therapy Disulfiram, Acamprosate 
Malta No No Yes No Minnesota model Disulfiram 
Netherlands Yes No No Yes MET, CBT, CRA Disulfiram, Naltrexone, Acamprosate 
Poland Yes No Yes Yes CBT, self-help (AA) Disulfiram, Acamprosate 
Portugal No No Yes Yes CBT, 12-step treatment Acamprosate, Disulfiram 
Romania No No Yes Yes Minnesota model, AA Rarely Naltrexone 
Slovakia No No Yes Yes CBT Acamprosate 
Slovenia Yes No Yes Yes  psychodynamic therapy, CBT, MET Naltrexone 
Spain No Yes Yes Yes CBT, group therapy Disulfiram, Naltrexone, Topiramate, Acamprosate 
Sweden Yes No Possible  Yes CBT, 12-step, MI, CRA, BI Naltrexone, Topiramate, Acamprosate 
United Kingdom Yes Yes Possible  Yes CBT, MET, 12-step, psychosocial Disulfiram, Acamprosate 







mainly CBT, MET, BI, group/family, 
sometimes Minnesota Model, AA 
Disulfiram, Acamprosate, Naltrexone 
Iceland Yes No Yes No Minnesota model, BI, MI, CBT, family antipsychotic medication 
Norway No No ? Yes CBT Disulfiram, Acamprosate 
Switzerland No No Yes Yes CBT, psychodynamic therapies Acamprosate, Disulfiram, Naltrexone 
 
List of Abbreviations 
AA: Alcoholics Anonymous 
BI: brief interventions 
CBT: cognitive behavioural therapy 
CRA: community reinforcement approach 
MET: motivational enhancement therapy 
MI: motivational interviewing 
























































































































































Interventions Main results on exposure  
(effects assumed to be stable for 1 year) 
Risk relations Source 
MI and CBT 1 
For MI, an average drop of 15.8 g of pure alcohol per 
day was assumed (measured against no intervention; 
95% CI from -9.6 g to -21.8 g of pure alcohol). The effect 
after one year was very small and not significant 
(average: 1.2 g pure alcohol reduction per day), the 
average effect over the year was a 3.2 g reduction of 
pure alcohol per day (95% CI: -1.2 g to -5.2g pure 
alcohol per day).  
For CBT, almost the same effect was found in studies 
with a no-treatment control as the comparison condition 
(15.9 g of pure alcohol per day). In addition, Project 
Match did not find any significant differences160 between 
MI and CBT.  
We modelled the results based on a drop 15.8 g/day 
over the year. 
MI: reference 162 
CBT: reference 163  
MI and CBT 2 
An average drop of 21.8 g of pure alcohol per day was 
assumed as the upper limit of the CI for MI/CBT (see 
above). We assumed proportional CIs compared to the 
first MI/CBT scenario. 
reference 162  
BI 1 An average drop of 13.5 g of pure alcohol per day with a 
95% CI from -2.7 to -24.5 of pure alcohol. 
references 147 and164  
BI 2 
An average reduction of the RR for mortality by 0.6 (95% 
CI: 0.40 to 0.91). This scenario represents the “best 
case” for BI, as hospitalization is linked to mortality, and 
AD plays an important role in mediating and moderating 
this premature mortality (e.g. references 165-166). 
However, similar effects were obtained in a meta-
analysis of all BIs.167  









Overall, for 55.0% of the patient population a reduction 
in drinking by 13% on average; for 18.1% of the patient 
population a reduction in drinking by 50%; and for 26.8% 
of the population abstinence. 
The usual dose-dependent 
risk relations between average 
consumption of alcohol and 
disease outcomes were used, 
multiplied by 2 to account for 
the overall higher mortality risk 
of people with AD.110 For 
injury, the same RR was used 
for AD; and for non-dependent 
people, the RR from reference 
161 was used. 
Pooled estimates of 
references 158 and 159. 
For this simulation we 
are concerned about the 
differences in 
consumption between 
baseline and follow-up 



































































































































































































































































AAF = Pabs +PformerRR former + Pcurrent (x)RRcurrent (x)dx −10
150∫







































AAF = Pabs +Pcurrent(non−binge)RRcurrent (non−binge) +Pcurrent (binge)RRcurrent (binge) −1




































































































































  Mouth and oropharynx cancer  C00‐C14  See references 192–193 (based on Relative Risks from reference 161) 
  Esophageal cancer  C15  See references 192–193 (based on Relative Risks from reference 161) 
  Liver cancer  C22  See references 192–193 (based on Relative Risks from reference 161) 
  Laryngeal cancer  C32  See references 192–193 (based on Relative Risks from reference 161) 
  Breast cancer  C50  See references 192–193 (based on Relative Risks from reference 161) 
  Colon cancer  C18   See references 192–193 (based on Relative Risks from reference 161) 
  Rectal cancer  C20  See references 192–193 (based on Relative Risks from reference 161) 
Diabetes 
  Diabetes mellitus  E10‐E14  See reference 194 
Neuropsychiatric conditions 
  Alcoholic psychosis (part of AUD)  F10.0, F10.3‐F10.9  100% AAF per definition 
  Alcohol abuse (part of AUD)  F10.1  100% AAF per definition 
  Alcohol dependence (part of AUD)  F10.2  100% AAF per definition 
  Epilepsy  G40‐G41  See reference 195 
Cardiovascular diseases 
  Hypertensive disease  I10‐I15  See reference 196 
  Ischemic heart disease  I20‐I25  See reference 46 for volume; 35 for pattern 
  Cardiac arrhythmia  I47‐I49  See reference 197 
  Ischemic stroke  I60‐I62  See reference 198 




  Cirrhosis of the liver  K70, K74  See reference 61 
  Acute and chronic pancreatitis  K85, K86.1  See reference 199 
Respiratory infections 
  Lower respiratory infection  J10–J18, J20–J22  See reference 200 
Conditions arising before birth 
  Low birth weight (as defined by the GBD)  P05‐P07  See reference 201 
Unintentional injuries 
  Motor‐vehicle accident  §  See reference 202 for Relative Risk; methodology adopted from 182 
  Poisoning  X40‐X49  See reference 202 for Relative Risk; methodology adopted from 182 
  Falling  W00‐W19  See reference 202 for Relative Risk; methodology adopted from 182 
  Fires  X00‐X09  See reference 202 for Relative Risk; methodology adopted from 182 









  Self‐inflicted injury  X60‐X84 and Y87.0  See reference 202 for Relative Risk; methodology adopted from 182 
  Homicide  X85‐Y09, Y87.1  See reference 202 for Relative Risk; methodology adopted from 182 
  Other intentional injury    See reference 202 for Relative Risk; methodology adopted from 182 
§ V021–V029, V031–V039, V041–V049, V092, V093, V123–V129, V133–V139, V143–V149, V194–V196, V203–V209, V213–V219, V223–
V229, V233–V239, V243–V249,V253–V259, V263–V269, V273–V279, V283–V289, V294–V299, V304–V309, V314–V319, V324–V329, V334–
V339, V344–V349, V354–V359, V364–V369, V374–V379, V384–V389, V394–V399, V404–V409, V414–V419, V424–V429, V434–V439, 
V444–V449, V454–V459, V464–V469, V474–V479, V484–V489, V494–V499, V504–V509, V514–V519, V524–V529, V534–V539, V544–V549, 
V554–V559, V564–V569, V574–V579, V584–V589, V594–V599, V604–V609, V614–V619, V624–V629, V634–V639, V644–V649, V654–V659, 
V664–V669, V674–V679, V684–V689, V694–V699, V704–V709, V714–V719, V724–V729, V734–V739, V744–V749, V754–V759, V764–V769, 
V774–V779, V784–V789, V794–V799, V803–V805, V811, V821, V830–V833, V840–V843, V850–V853, V860–V863, V870–V878, V892.  





























Austria 383 202 560  1,543 964 2,114  1,925 1,167 2,674 
Belgium 513 237 785  1,385 760 1,998  1,898 997 2,783 
Bulgaria 302 -139 734  1,620 646 2,575  1,922 507 3,309 
Cyprus 10 -6 25  14 -16 42  24 -22 67 
Czech Republic 642 222 1,055  3,199 1,851 4,246  3,842 2,072 5,302 
Denmark 338 176 497  1,037 681 1,388  1,375 857 1,885 
Estonia 194 106 281  1,153 764 1,464  1,347 870 1,746 
Finland 276 46 503  1,235 419 2,044  1,511 465 2,547 
France 2,998 1,898 4,089  12,284 8,401 16,134  15,282 10,298 20,223 
Germany 3,953 1,859 6,001  13,625 8,649 18,505  17,578 10,508 24,506 
Greece 272 29 511  529 11 1,033  802 40 1,544 
Hungary 1,232 584 1,867  5,483 3,835 7,114  6,716 4,419 8,981 
Iceland 3 -2 9  7 -8 22  10 -11 31 
Ireland 155 66 242  395 150 636  550 216 878 
Italy 1,525 282 2,749  3,794 1,467 6,070  5,320 1,749 8,819 
Latvia 356 136 573  2,011 1,335 2,244  2,366 1,472 2,817 
Lithuania 339 157 518  2,741 1,784 3,634  3,080 1,941 4,152 
Luxembourg 20 3 37  80 38 122  101 42 159 
Malta 5 -3 13  10 -3 23  15 -6 36 
Netherlands 539 250 823  1,049 474 1,614  1,588 724 2,437 
Norway 83 -17 181  315 12 614  397 -6 795 
Poland 2,072 372 3,761  12,426 6,921 17,878  14,498 7,293 21,639 
Portugal 668 324 1,009  2,250 1,285 3,172  2,917 1,610 4,181 
Romania 3,516 1,678 5,340  11,659 7,574 14,463  15,175 9,252 19,804 
Slovakia 378 -23 775  2,113 954 3,121  2,491 931 3,896 
Slovenia 165 88 242  780 505 1,037  945 593 1,279 
Spain 1,611 883 2,336  5,974 3,453 8,474  7,585 4,336 10,811 
Sweden 214 53 372  579 240 910  794 293 1,282 
Switzerland 251 147 352  719 416 1,018  970 563 1,370 
United Kingdom 2,607 908 4,274  5,482 2,235 8,656  8,089 3,143 12,930 
European Union 25,284 10,390 39,973  94,451 55,376 130,712  119,736 65,766 170,685 
For comparison            
Russia 44,976 21,315 68,496  232,936 148,036 277,250  277,912 169,350 345,746 
Regions            
Central-West and Western 
Europe 
11,419 5,570 17,164  36,561 22,087 50,797  47,980 27,658 67,960 
Central-East and Eastern 
Europe 
9,197 3,181 15,148  43,186 26,168 57,777  52,383 29,349 72,924 
Nordic Countries 914 257 1,562  3,173 1,343 4,978  4,088 1,600 6,539 
































Austria 8.2% 4.6% 11.8%  17.4% 10.9% 23.9%  14.4% 8.9% 19.9% 
Belgium 7.9% 4.1% 11.7%  12.8% 7.3% 18.2%  11.1% 6.2% 15.9% 
Bulgaria 3.7% -0.9% 8.3%  9.8% 4.4% 15.2%  7.9% 2.7% 13.0% 
Cyprus 2.6% -0.8% 6.0%  3.1% -0.7% 6.7%  2.8% -0.8% 6.4% 
Czech Republic 8.4% 3.5% 13.3%  21.0% 12.5% 27.7%  17.0% 9.6% 23.0% 
Denmark 8.2% 4.6% 11.8%  16.8% 11.0% 22.6%  13.5% 8.6% 18.4% 
Estonia 13.2% 8.0% 18.4%  33.5% 22.5% 41.9%  28.0% 18.5% 35.5% 
Finland 8.3% 2.2% 14.3%  18.4% 7.8% 29.1%  15.2% 6.0% 24.4% 
France 8.7% 5.6% 11.7%  17.0% 11.4% 22.5%  14.4% 9.7% 19.2% 
Germany 7.9% 4.2% 11.5%  14.9% 9.7% 20.1%  12.5% 7.8% 17.1% 
Greece 4.9% 0.8% 9.0%  5.4% 0.9% 9.9%  5.2% 0.8% 9.6% 
Hungary 10.5% 5.5% 15.4%  22.6% 15.9% 29.3%  18.9% 12.7% 25.0% 
Iceland 2.6% -1.5% 6.5%  4.6% -2.1% 11.3%  3.7% -2.0% 9.4% 
Ireland 7.0% 3.3% 10.8%  12.0% 5.4% 18.6%  10.2% 4.6% 15.7% 
Italy 5.0% 1.3% 8.5%  7.2% 3.1% 11.1%  6.4% 2.5% 10.3% 
Latvia 12.8% 5.9% 19.6%  34.0% 23.2% 37.1%  27.8% 18.1% 31.9% 
Lithuania 10.1% 5.3% 14.7%  32.8% 21.9% 42.7%  26.9% 17.6% 35.5% 
Luxembourg 7.9% 2.4% 13.3%  16.1% 8.1% 24.0%  13.3% 6.2% 20.4% 
Malta 2.4% -0.8% 5.5%  3.7% 0.1% 7.2%  3.2% -0.3% 6.6% 
Netherlands 5.1% 2.5% 7.8%  7.5% 3.6% 11.3%  6.5% 3.1% 9.8% 
Norway 3.5% 0.0% 7.0%  8.1% 1.3% 14.8%  6.4% 0.8% 11.9% 
Poland 6.9% 1.9% 11.9%  18.9% 10.9% 26.7%  15.4% 8.3% 22.4% 
Portugal 9.9% 5.1% 14.7%  16.2% 9.1% 22.9%  14.3% 8.0% 20.5% 
Romania 14.4% 7.3% 21.5%  25.4% 16.5% 31.4%  22.0% 13.6% 28.3% 
Slovakia 9.0% 0.9% 16.9%  21.7% 10.6% 31.3%  18.2% 7.9% 27.3% 
Slovenia 11.6% 6.5% 16.7%  24.7% 16.1% 32.8%  20.8% 13.2% 28.0% 
Spain 8.5% 4.7% 12.2%  14.1% 7.9% 20.3%  12.4% 7.0% 17.8% 
Sweden 4.3% 1.3% 7.3%  8.4% 4.0% 12.8%  6.8% 2.9% 10.7% 
Switzerland 6.7% 4.1% 9.3%  12.3% 7.0% 17.5%  10.2% 5.9% 14.4% 
United Kingdom 7.1% 3.1% 11.1%  10.5% 5.0% 15.9%  9.2% 4.3% 14.0% 
European Union 8.0% 3.7% 12.2%  16.0% 9.6% 22.0%  13.4% 7.7% 18.8% 
For comparison            
Russia 15.5% 7.8% 23.2%  33.9% 21.9% 40.1%  29.3% 18.4% 35.8% 
Regions            
Central-West and Western 
Europe 
7.7% 4.1% 11.1%  14.0% 8.6% 19.3%  11.8% 7.1% 16.5% 
Central-East and Eastern 
Europe 
9.6% 3.9% 15.2%  21.8% 13.5% 28.9%  18.1% 10.6% 24.7% 
Nordic Countries 6.1% 2.1% 10.1%  13.3% 6.3% 20.2%  10.7% 4.8% 16.5% 

























Austria 2.2% 1.3% 3.1%  14.2% 12.8% 15.6%  7.6% 6.4% 8.7% 
Belgium 1.8% 0.8% 2.7%  7.6% 6.2% 9.1%  4.3% 3.0% 5.5% 
Bulgaria 0.4% -0.9% 1.6%  10.3% 7.9% 12.8%  5.3% 3.4% 7.1% 
Cyprus -2.8% -4.2% -1.4%  7.1% 5.6% 8.5%  1.9% 0.4% 3.3% 
Czech Republic 1.3% -0.2% 2.7%  15.1% 12.6% 17.5%  7.9% 5.9% 9.8% 
Denmark 2.0% 1.0% 2.9%  14.0% 12.5% 15.4%  7.2% 5.9% 8.4% 
Estonia 4.1% 3.0% 5.2%  26.8% 24.6% 28.9%  15.9% 14.2% 17.5% 
Finland 2.6% 1.1% 4.0%  19.1% 16.7% 21.4%  10.4% 8.5% 12.3% 
France 2.8% 1.9% 3.6%  15.5% 14.1% 16.9%  8.5% 7.4% 9.6% 
Germany 1.9% 0.8% 2.9%  16.0% 14.5% 17.4%  8.3% 7.0% 9.5% 
Greece 1.6% 0.2% 2.9%  12.2% 10.2% 14.2%  6.6% 4.8% 8.2% 
Hungary 4.9% 3.6% 6.0%  33.5% 31.7% 35.2%  19.3% 17.7% 20.8% 
Iceland 1.5% 0.7% 2.3%  10.0% 8.4% 11.5%  5.2% 3.9% 6.4% 
Ireland 2.8% 1.9% 3.6%  14.8% 13.5% 16.1%  8.3% 7.1% 9.3% 
Italy 0.4% -0.6% 1.4%  2.4% 0.6% 4.2%  1.3% -0.1% 2.7% 
Latvia 4.4% 2.9% 5.9%  28.0% 25.5% 30.2%  16.6% 14.6% 18.5% 
Lithuania 4.9% 3.8% 5.8%  30.4% 28.2% 32.5%  18.4% 16.7% 20.0% 
Luxembourg 2.5% 1.2% 3.7%  14.7% 12.8% 16.5%  8.0% 6.5% 9.6% 
Malta -0.2% -1.5% 1.0%  8.2% 6.4% 9.9%  3.5% 1.9% 5.0% 
Netherlands 2.0% 1.2% 2.7%  17.7% 16.7% 18.7%  9.1% 8.2% 10.0% 
Norway 6.2% 5.2% 7.2%  26.1% 24.7% 27.4%  15.6% 14.4% 16.8% 
Poland 1.9% 0.7% 3.0%  13.6% 11.0% 16.3%  7.7% 5.7% 9.6% 
Portugal 3.4% 2.2% 4.6%  13.9% 11.8% 16.0%  8.5% 6.8% 10.2% 
Romania 3.5% 1.8% 5.1%  17.7% 14.4% 20.9%  10.6% 8.0% 13.0% 
Slovakia 1.6% -0.1% 3.4%  22.8% 19.9% 25.8%  12.8% 10.4% 15.2% 
Slovenia 2.4% 1.2% 3.6%  13.0% 10.6% 15.4%  7.3% 5.5% 9.1% 
Spain 1.0% 0.1% 1.9%  5.4% 3.6% 7.3%  3.1% 1.7% 4.5% 
Sweden 5.7% 4.9% 6.5%  21.2% 20.2% 22.3%  12.5% 11.6% 13.5% 
Switzerland 2.2% 1.5% 2.9%  13.7% 12.5% 14.8%  7.3% 6.3% 8.3% 
United Kingdom 3.5% 2.4% 4.5%  19.0% 17.7% 20.2%  10.7% 9.4% 11.9% 
European Union 2.2% 1.1% 3.3%  14.5% 12.7% 16.2%  7.9% 6.5% 9.4% 
For comparison            
Russia 6.5% 4.6% 8.3%  30.0% 27.1% 32.8%  19.6% 17.1% 22.0% 
Regions            
Central-West and Western 
Europe 
2.6% 1.6% 3.5%  16.3% 14.9% 17.6%  8.8% 7.6% 9.9% 
Central-East and Eastern 
Europe 
2.5% 1.2% 3.9%  18.1% 15.4% 20.7%  10.3% 8.2% 12.3% 
Nordic Countries 4.2% 3.1% 5.2%  20.0% 18.5% 21.5%  11.3% 10.0% 12.6% 

























Austria 3.8% 2.2% 5.3%  15.6% 11.9% 19.3%  10.1% 7.3% 12.8% 
Belgium 3.5% 1.7% 5.2%  10.1% 6.7% 13.4%  6.9% 4.2% 9.5% 
Bulgaria 1.6% -0.9% 4.0%  10.1% 5.9% 14.1%  6.6% 3.0% 10.0% 
Cyprus -1.6% -3.5% 0.2%  5.6% 3.3% 7.8%  2.2% 0.0% 4.2% 
Czech Republic 3.6% 1.0% 6.1%  18.1% 12.6% 22.8%  11.9% 7.5% 15.7% 
Denmark 3.8% 2.1% 5.5%  15.3% 11.9% 18.6%  9.6% 6.9% 12.2% 
Estonia 7.7% 5.0% 10.4%  31.0% 23.3% 37.1%  22.6% 16.6% 27.5% 
Finland 4.2% 1.4% 6.9%  18.8% 12.6% 24.9%  12.3% 7.5% 17.1% 
France 4.3% 2.9% 5.7%  16.2% 12.9% 19.6%  10.8% 8.3% 13.3% 
Germany 3.6% 1.8% 5.3%  15.5% 12.4% 18.6%  9.9% 7.3% 12.4% 
Greece 2.5% 0.4% 4.5%  9.1% 5.9% 12.3%  6.1% 3.3% 8.7% 
Hungary 7.1% 4.4% 9.7%  27.2% 22.6% 31.8%  19.1% 15.2% 22.9% 
Iceland 1.8% 0.1% 3.4%  7.9% 4.4% 11.4%  4.7% 2.1% 7.3% 
Ireland 4.0% 2.2% 5.6%  13.6% 10.0% 17.2%  9.0% 6.2% 11.7% 
Italy 1.6% -0.1% 3.3%  4.6% 1.7% 7.3%  3.1% 0.8% 5.4% 
Latvia 7.9% 4.1% 11.6%  31.7% 24.0% 34.6%  22.8% 16.5% 26.0% 
Lithuania 6.9% 4.4% 9.2%  31.9% 24.3% 38.9%  23.0% 17.2% 28.5% 
Luxembourg 3.9% 1.5% 6.3%  15.3% 10.7% 19.8%  10.0% 6.4% 13.5% 
Malta 0.5% -1.3% 2.2%  6.4% 3.8% 8.8%  3.4% 1.2% 5.5% 
Netherlands 2.9% 1.6% 4.2%  13.7% 11.6% 15.8%  8.2% 6.4% 9.9% 
Norway 5.5% 3.8% 7.1%  19.2% 15.7% 22.6%  12.5% 9.8% 15.1% 
Poland 3.5% 1.1% 6.0%  16.5% 10.9% 22.0%  11.3% 6.9% 15.6% 
Portugal 5.3% 3.0% 7.6%  15.0% 10.5% 19.4%  10.9% 7.3% 14.5% 
Romania 7.6% 3.9% 11.3%  22.1% 15.6% 26.9%  16.3% 10.8% 20.7% 
Slovakia 4.0% 0.2% 7.7%  22.3% 15.1% 28.6%  15.2% 9.2% 20.6% 
Slovenia 5.1% 2.7% 7.4%  19.0% 13.4% 24.3%  13.1% 8.8% 17.1% 
Spain 2.9% 1.2% 4.5%  9.4% 5.6% 13.2%  6.6% 3.7% 9.5% 
Sweden 5.3% 4.0% 6.7%  16.4% 14.0% 18.7%  10.7% 8.8% 12.6% 
Switzerland 3.3% 2.1% 4.5%  13.1% 10.3% 15.9%  8.3% 6.2% 10.3% 
United Kingdom 4.5% 2.6% 6.4%  15.6% 12.6% 18.5%  10.1% 7.6% 12.6% 
European Union 3.9% 1.9% 5.9%  15.2% 11.2% 19.0%  10.1% 6.9% 13.1% 
For comparison            
Russia 11.0% 6.2% 15.8%  32.8% 23.4% 37.9%  25.9% 17.9% 30.9% 
            
Regions            
Central-West and Western 
Europe 
4.0% 2.3% 5.6%  15.3% 12.2% 18.4%  9.9% 7.4% 12.3% 
Central-East and Eastern 
Europe 
5.0% 2.1% 7.9%  20.2% 14.3% 25.3%  14.1% 9.4% 18.3% 
Nordic Countries 4.7% 2.9% 6.5%  17.2% 13.4% 21.0%  11.1% 8.2% 14.0% 
















Cancer  8,770 4,616  20.0% 35.2%
CVD (other than IHD)  2,189 542  5.0% 4.1%
Mental and neurological disorders  6,836 1,679  15.6% 12.8%
Liver cirrhosis  12,443 4,905  28.4% 37.4%
Unintentional injury  5,739 530  13.1% 4.0%
Intentional injury  6,935 606  15.8% 4.6%
Other detrimental  964 238  2.2% 1.8%
Total detrimental  43,875 13,116  100.0% 100.0%
Beneficial effects   
IHD  (7,106) (1,097)  97.2% 64.6%
Other beneficial  (207) (600)  2.8% 35.4%












Cancer  5,124 2,010  10.7% 20.3%
CVD (other than IHD)  4,403 2,023  9.2% 20.5%
Mental and neurological disorders  2,994 448  6.3% 4.5%
Liver cirrhosis  11,127 3,941  23.3% 39.8%
Unintentional injury  14,685 864  30.8% 8.7%
Intentional injury  7,435 320  15.6% 3.2%
Other detrimental  1,974 285  4.1% 2.9%
Total detrimental  47,741 9,891  100.0% 100.0%
Beneficial effects   
IHD  (4,524) (427)  99.3% 61.5%
Other beneficial  (32) (268)  0.7% 38.5%
















Cancer  407 357  10.4% 33.7%
CVD (other than IHD)  204 28  5.2% 2.6%
Mental and neurological disorders  792 175  20.3% 16.5%
Liver cirrhosis  985 355  25.2% 33.4%
Unintentional injury  857 74  21.9% 7.0%
Intentional injury  599 56  15.3% 5.3%
Other detrimental  63 17  1.6% 1.6%
Total detrimental  3,908 1,062  100.0% 100.0%
Beneficial effects   
IHD  (709) (85)  96.5% 58.0%
Other beneficial  (26) (62)  3.5% 42.0%












Cancer  3,284 1,842  21.5% 40.5%
CVD (other than IHD)  1,181 538  7.7% 11.8%
Mental and neurological disorders  463 86  3.0% 1.9%
Liver cirrhosis  4,165 1,411  27.3% 31.0%
Unintentional injury  3,874 349  25.4% 7.7%
Intentional injury  1,837 218  12.0% 4.8%
Other detrimental  475 102  3.1% 2.3%
Total detrimental  15,279 4,547  100.0% 100.0%
Beneficial effects   
IHD  (2,633) (220)  97.3% 48.2%
Other beneficial  (74) (237)  2.7% 51.8%

















Cancer  126,235 81,615 7.4%  18.4%
CVD (other than IHD)  37,134 ‐ 2.2%  0.0%
Mental and neurological disorders  991,447 227,115 58.4%  51.2%
Liver cirrhosis  222,449 100,779 13.1%  22.7%
Unintentional injury  150,413 15,590 8.9%  3.5%
Intentional injury  147,055 12,456 8.7%  2.8%
Other detrimental  24,208 6,366 1.4%  1.4%
Total detrimental  1,698,940 443,920 100.0%  100.0%
Beneficial effects   
IHD  (132,108) (45,336) 94.3%  45.8%
Other beneficial  (8,056) (50,157) 5.7%  50.7%
CVD other than IHD  ‐ (3,530) 0.0%  3.6%












Cancer  75,905 33,349 5.4%  12.3%
CVD (other than IHD)  68,122 24,871 4.8%  9.2%
Mental and neurological disorders  497,910 93,774 35.3%  34.7%
Liver cirrhosis  204,754 79,656 14.5%  29.5%
Unintentional injury  365,247 23,812 25.9%  8.8%
Intentional injury  153,543 6,747 10.9%  2.5%
Other detrimental  45,330 8,117 3.2%  3.0%
Total detrimental  1,410,811 270,326 100.0%  100.0%
Beneficial effects   
IHD  (83,826) (27,714) 98.0%  59.5%
Other beneficial  (1,724) (18,857) 2.0%  40.5%















Cancer  5,772 6,224  3.2%  12.3%
CVD (other than IHD)  3,324 ‐  1.8%  0.0%
Mental and neurological disorders  122,365 33,659  66.8%  66.8%
Liver cirrhosis  17,313 7,054  9.5%  14.0%
Unintentional injury  20,021 1,916  10.9%  3.8%
Intentional injury  12,774 1,162  7.0%  2.3%
Other detrimental  1,563 404  0.9%  0.8%
Total detrimental  183,132 50,420  100.0%  100.0%
Beneficial effects     
IHD  (12,773) (4,188)  93.0%  41.7%
Other beneficial  (954) (5,023)  7.0%  50.0%
CVD other than IHD  ‐ (837)  0.0%  8.3%












Cancer  47,163 33,296 10.9%  26.4%
CVD (other than IHD)  20,762 5,067 4.8%  4.0%
Mental and neurological disorders  132,266 42,064 30.7%  33.4%
Liver cirrhosis  72,625 27,270 16.8%  21.7%
Unintentional injury  105,983 10,322 24.6%  8.2%
Intentional injury  39,203 4,483 9.1%  3.6%
Other detrimental  13,066 3,402 3.0%  2.7%
Total detrimental  431,066 125,903 100.0%  100.0%
Beneficial effects   
IHD  (51,530) (12,009) 91.6%  35.1%
Other beneficial  (4,731) (22,217) 8.4%  64.9%

















Country Women Men Women 
affected 
Men affected Year 
Austria 2.5 7.5 85,000 255,000 2008 
Belgium 1.6 4.7 68,200 190,500 2001 
Bulgaria 1.2 6.4 39,500 197,900 2004 
Cyprus 1.4 4.7 4,700 14,600 2004 
Czech Republic 0.7 4.5 30,000 182,800 2004 
Denmark 1.6 4.3 35,200 88,600 2005 
Estonia 1.7 9.9 10,500 48,000 2004 
Finland 1.5 6.1 32,900 123,800 2000 
France 1.3 4.7 314,100 1,073,800 2001-2002 
Germany 1.1 4.7 378,900 1,558,200 1997-1999 
Greece 1.3 4.2 59,100 188,200 2004 
Hungary 3.2 16.5 140,700 632,600 2004 
Iceland 0.9 3 970 3,300 2004 
Ireland 1.8 5.8 28,300 90,400 2004 
Italy 0.4 0.7 104,900 162,600 2001-2003 
Latvia 1.3 7.6 13,800 63,800 2004 
Lithuania 1.6 8.9 23,800 110,100 2004 
Luxembourg 1.2 4.7 2,200 8,200 2000 
Malta 0.7 2.5 1,100 4,000 2004 
Netherlands 0.4 0.9 28,300 56,400 2007/2009 
Norway 2.9 9.4 54,600 164,600 1994-1997 
Poland 1.4 7.7 222,300 1,111,900 2004 
Portugal 1.4 4.9 64,500 201,500 2004 
Romania 0.6 2 54,400 164,700 2007 
Slovakia 1.1 10.2 21,700 192,800 2000/2001 
Slovenia 2 10.5 14,500 75,500 1999 
Spain 0.2 1.2 31,200 186,000 2000/2001 
Sweden 2.8 6.7 101,000 236,700 1998-2003 
Switzerland 1.4 7.2 42,300 206,800 2007 
UK 3.2 8.7 796,400 1,994,700 2007 
EU 1.3 4.8 2,707,200 9,213,300   
For comparison 









18-64 women in 
% 
AD prevalence 





Central-West and Western Europe 1.94 6.18 1,519,400 4,915,600 
Central-East and Eastern Europe  1.49 7.84 510,700 2,635,700 
Nordic Countries 2.70 7.43 205,810 581,500 





15+ women in % 
AD prevalence 





Central-West and Western Europe 1.69 5.59 1,743,800 5,434,000 
Central-East and Eastern Europe  1.33 7.16 571,200 2,780,100 
Nordic Countries 2.26 6.52 224,670 617,000 





























































































& other: 1st 
estimate 
Outpatient 









if not WHO database 
(see note below) 
Austria 85,000 255,000 22,400 10,577 41,608 10% 19%  
Belgium 68,200 190,500 11,866 13,065 22,041 10% 13%  
Bulgaria 39,500 197,900 10010 10,112 18,593 8% 12%  
Cyprus 4,700 14,600 68 1,015 126 6% 1%  
Czech 
Republic 
30,000 182,800 14,522 13,158 26,974 13% 20%  
Denmark 35,200 88,600 6,549 6,664 12,165 11% 15%  
Estonia 10,500 48,000 2467 1,726 4,582 7% 12%  
Finland 32,900 123,800 17,327 6,565 32,185 15% 32%  
France 314,100 1,073,800 94,569 75,399 175,660 12% 19%  
Germany 378,900 1,558,200 55,171 118,743 118,743 9% 9% Reference 203 
Greece 59,100 188,200 10427 14,413 19,368 10% 12%  




Iceland 970 3,300 419 364 778 18% 28%  
Ireland 28,300 90,400 5005 4,973 9,297 8% 12%  
Italy 104,900 162,600 19,613 11,783 11,783 12% 12% Reference 204 
Latvia 13,800 63,800 11,736 2,983 21,799 19% 43%  
Lithuania 23,800 110,100 7,671 4,318 14,249 9% 16%  
Luxembourg 2,200 8,200 1,518 563 2,820 20% 42%  
Malta 1,100 4,000 225 504 418 14% 13%  
Netherlands 28,300 56,400 3,564 20,182 6,620 28% 12%  
Norway 54,600 164,600 2,869 5,952 5,329 4% 4%  
Poland 222,300 1,111,900 15,699 48,402 29,161 5% 3%  
Portugal 64,500 201,500 11216 13,446 20,833 9% 12%  
Romania 54,400 164,700 9238 27,623 17,160 17% 12%  
Slovakia 21,700 192,800 11,901 6,789 22,106 9% 16%  
Slovenia 14,500 75,500 2,527 2,600 4,694 6% 8%  
Spain 31,200 186,000 7,679 56,248 14,264 29% 10%  




Switzerland 42,300 206,800 13,688 9,901 25,425 9% 16%  
UK 796,400 1,994,700 42,503 74,844 78,949 4% 4%  
EU 2,707,200 9,213,300 414,335 623,944 803,442 9% 10%  
 
Notes: The green-shaded information is from the European Hospital Morbidity Database. Regarding sources (final column), most data are drawn 




































10% shift  20% shift  30% shift  40% shift 
Pharmacotherapy  2,459 (95% CI:795 – 4,122)  4,980 (95% CI: 1,711 – 8,248)  7,564 (95% CI:2,713 – 12,415)  10,040 (95% CI: 3,740 – 16,341) 
MI/CBT  1,020 (95% CI: 627‐1,414)  2,051 (95% CI: 1,260‐2,841)  3,105 (95% CI: 1,911‐4,299)  4,160 (95% CI: 2,561‐5,760) 
MI/CBT higher effectiveness  1,217 (95% CI: 680‐1,754)  2,452 (95% CI: 1,375‐3,530)  3,698 (95% CI: 2,082‐5,314)  4,985 (95% CI: 2,816‐7,154) 
BI hospital 1  995 (95% CI: 604‐1,385)  2,000 (95% CI: 1,218‐2,782)  3,014 (95% CI: 1,836‐4,192)  4,051 (95% CI: 2,469‐5,633) 




10% shift  20% shift  30% shift  40% shift 
Pharmacotherapy  3.3% (95% CI: 0.7‐10.1)  6.6% (95% CI: 1.6‐20.3)  10.0% (95% CI: 2.5‐30.5)  13.3% (95% CI: 3.4‐40.1) 
MI/CBT  1.4% (95% CI: 0.6‐3.5)  2.7% (95% CI: 1.1‐7.0)  4.1% (95% CI: 1.7‐10.6)  5.5% (95% CI: 2.3‐14.2) 
MI/CBT higher 
effectiveness  1.6% (95% CI: 0.6‐4.3)  3.3% (95% CI: 1.3‐8.7)  4.9% (95% CI: 1.9‐13.1)  6.6% (95% CI: 2.6‐17.6) 
BI hospital 1  1.3% (95% CI: 0.5‐3.4)  2.7% (95% CI: 1.1‐6.8)  4.0% (95% CI: 1.7‐10.3)  5.4% (95% CI: 2.2‐13.8) 




10% shift  20% shift  30% shift  40% shift 
Pharmacotherapy  0.4% (95% CI: 0.1‐0.6)  0.7% (95% CI: 0.3‐1.2)  1.1% (95% CI: 0.4‐1.8)  1.5% (95% CI: 0.5‐2.4) 
MI/CBT  0.2% (95% CI: 0.1‐0.2)  0.3% (95% CI: 0.2‐0.4)  0.5% (95% CI: 0.3‐0.6)  0.6% (95% CI: 0.4‐0.8) 
MI/CBT higher 
effectiveness  0.2% (95% CI: 0.1‐0.3)  0.4% (95% CI: 0.2‐0.5)  0.5% (95% CI: 0.3‐0.8)  0.7% (95% CI: 0.4‐1.1) 
BI hospital 1  0.1% (95% CI: 0.1‐0.2)  0.3% (95% CI: 0.2‐0.4)  0.4% (95% CI: 0.3‐0.6)  0.6% (95% CI: 0.4‐0.8) 








10% shift  20% shift  30% shift  40% shift 
Pharmacotherapy  416 (95% CI:103‐729)  838 (95% CI: 214‐1,461)  1,269 (95% CI: 336‐2,202)  1,704 (95% CI: 462‐2,945) 
MI/CBT  248 (95% CI: 70‐499)  573 (95% CI: 151‐996)  857 (95% CI: 230‐1,484)  1,148 (95% CI: 320‐1,976) 
MI/CBT higher effectiveness  324 (95% CI: 63‐586)  651 (95% CI: 139‐1,162)  985 (95% CI: 226‐1,745)  1,315 (95% CI: 311‐2,320) 
BI hospital 1  266 (95% CI: 75‐458)  540 (95% CI: 160‐920)  813 (95% CI: 245‐1,381)  1,080 (95% CI: 335‐1,825) 




10% shift  20% shift  30% shift  40% shift 
Pharmacotherapy  2.3% (95% CI: 0.3‐10.9)  4.6% (95% CI: 0.7‐21.9)  6.9% (95% CI: 1.1‐32.9)  9.3% (95% CI: 1.5‐44.0) 
MI/CBT  1.5% (95% CI: 0.2‐7.4)  3.1% (95% CI: 0.5‐14.8)  4.7% (95% CI: 0.8‐22.0)  6.2% (95% CI: 1.1‐29.3) 
MI/CBT higher 
effectiveness  1.8% (95% CI: 0.2‐8.7)  3.5% (95% CI: 0.5‐17.2)  5.3% (95% CI: 0.8‐25.9)  7.1% (95% CI: 1.0‐34.4) 
BI hospital 1  1.4% (95% CI: 0.2‐6.8)  2.9% (95% CI: 0.5‐13.7)  4.4% (95% CI: 0.8‐20.6)  5.9% (95% CI: 1.1‐27.2) 




10% shift  20% shift  30% shift  40% shift 
Pharmacotherapy  0.1% (95% CI: 0.0‐0.2)  0.2% (95% CI: 0.1‐0.4)  0.4% (95% CI:0.1‐0.6)  0.5% (95% CI:0.1‐0.8) 
MI/CBT  0.1% (95% CI: 0.0‐0.1)  0.2% (95% CI: 0.0‐0.3)  0.2% (95% CI: 0.1‐0.4)  0.3% (95% CI: 0.1‐0.6) 
MI/CBT higher 
effectiveness  0.1% (95% CI: 0.0‐0.2)  0.2% (95% CI: 0.0‐0.3)  0.3% (95% CI: 0.1‐0.5)  0.4% (95% CI: 0.1‐0.7) 
BI hospital 1  0.1% (95% CI: 0.0‐0.1)  0.2% (95% CI: 0.0‐0.3)  0.2% (95% CI: 0.1‐0.4)  0.3% (95% CI: 0.1‐0.5) 















10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift 
Central‐West and Western Europe  1,199  2,415  3,658  4,748  3.4%  6.9%  10.5%  13.7%  0.4%  0.8%  1.2%  1.6% 
Central‐East and Eastern Europe   1,027  2,094  3,192  4,334  3.4%  6.9%  10.5%  14.3%  0.5%  0.9%  1.4%  1.9% 
Nordic Countries  139  284  431  584  4.5%  9.2%  13.9%  18.9%  0.5%  1.0%  1.6%  2.1% 




10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift 
Central‐West and Western Europe  250  496  753  1,008  2.9%  5.7%  8.6%  11.5%  0.2%  0.3%  0.5%  0.6% 
Central‐East and Eastern Europe   120  245  373  503  1.7%  3.5%  5.4%  7.2%  0.1%  0.2%  0.4%  0.5% 
Nordic Countries  32  66  99  133  3.7%  7.4%  11.2%  15.1%  0.0%  0.1%  0.1%  0.2% 




10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift 
Central‐West and Western Europe  556  1,115  1,691  2,266  1.6%  3.2%  4.9%  6.5%  0.2%  0.4%  0.6%  0.8% 
Central‐East and Eastern Europe   362  729  1,103  1,478  1.2%  2.4%  3.6%  4.9%  0.2%  0.3%  0.5%  0.7% 
Nordic Countries  65  130  196  263  2.1%  4.2%  6.3%  8.5%  0.2%  0.5%  0.7%  0.9% 






10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift 
Central‐West and Western Europe  173  351  523  705  2.0%  4.0%  6.0%  8.1%  0.1%  0.2%  0.3%  0.4% 
Central‐East and Eastern Europe   80  160  242  318  1.1%  2.3%  3.5%  4.5%  0.1%  0.2%  0.2%  0.3% 
Nordic Countries  21  43  64  86  2.4%  4.8%  7.3%  9.7%  0.1%  0.3%  0.4%  0.6% 




10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift 
Central‐West and Western Europe  643  1,294  1,948  2,625  1.9%  3.7%  5.6%  7.6% 
Central‐East and Eastern Europe   453  915  1,383  1,869  1.5%  3.0%  4.6%  6.2% 
Nordic Countries  76  154  233  312  2.5%  5.0%  7.5%  10.1% 




10% shift  20% shift  30% shift  10% shift  20% shift  30% shift  10% shift  20% shift  30% shift  10% shift  20% shift  30% shift 
Central‐West and Western Europe  176  358  543  721  1.9%  3.9%  5.9%  7.8%  0.1%  0.2%  0.3%  0.5% 
Central‐East and Eastern Europe   81  158  243  325  1.1%  2.1%  3.3%  4.4%  0.1%  0.2%  0.2%  0.3% 
Nordic Countries  23  46  70  93  2.6%  5.1%  7.7%  10.4%  0.1%  0.3%  0.4%  0.6% 






10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift 
Central‐West and Western Europe  544  1,090  1,650  2,213  1.6%  3.1%  4.7%  6.4%  0.2%  0.4%  0.6%  0.7% 
Central‐East and Eastern Europe   350  704  1,057  1,429  1.1%  2.3%  3.5%  4.7%  0.2%  0.3%  0.5%  0.6% 
Nordic Countries  63  127  192  257  2.0%  4.1%  6.2%  8.3%  0.2%  0.5%  0.7%  0.9% 




10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift  10% shift  20% shift  30% shift  40% shift 
Central‐West and Western Europe  162  335  503  670  1.9%  3.8%  5.8%  7.7%  0.1%  0.2%  0.3%  0.4% 
Central‐East and Eastern Europe   74  145  221  292  1.1%  2.1%  3.2%  4.2%  0.1%  0.1%  0.2%  0.3% 
Nordic Countries  21  41  62  83  2.3%  4.6%  7.0%  9.3%  0.1%  0.3%  0.4%  0.5% 




10% shift  20% shift  30% shift  10% shift  20% shift  30% shift  10% shift  20% shift  30% shift  10% shift  20% shift  30% shift 
Central‐West and Western Europe  1,157  2,335  3,532  4,757  3.3%  6.7%  10.2%  13.7%  0.4%  0.8%  1.2%  1.6% 
Central‐East and Eastern Europe   1,078  2,180  3,311  4,474  3.5%  7.2%  10.9%  14.7%  0.5%  1.0%  1.5%  2.0% 
Nordic Countries  137  277  420  565  4.4%  9.0%  13.5%  18.2%  0.5%  1.0%  1.5%  2.0% 









10% shift  20% shift  30% shift  10% shift  20% shift  30% shift  10% shift  20% shift  30% shift  10% shift  20% shift  30% shift 
Central‐West and Western Europe  214  434  650  875  2.5%  5.0%  7.4%  10.0%  0.1%  0.3%  0.4%  0.6% 
Central‐East and Eastern Europe   113  222  336  450  1.6%  3.2%  4.8%  6.4%  0.1%  0.2%  0.3%  0.4% 
Nordic Countries  28  56  84  113  3.1%  6.3%  9.5%  12.7%  0.2%  0.4%  0.5%  0.7% 
Southern Europe  24  48  72  97  1.1%  2.3%  3.4%  4.6%  0..0%  0.1%  0.1%  0.2% 
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